Surgical Margins in Cutaneous Melanoma (2 cm Versus 5 cm for Lesions Measuring Less Than 2.1-mm Thick)
|
|
- Jeremy Murphy
- 6 years ago
- Views:
Transcription
1 1941 Surgical Margins in Cutaneous Melanoma (2 cm Versus 5 cm for Lesions Measuring Less Than 2.1-mm Thick) Long-Term Results of a Large European Multicentric Phase III Study David Khayat, M.D., Ph.D. 1 Olivier Rixe, M.D. 1 Ginette Martin, M.D., Ph.D. 2 Claude Soubrane, M.D., Ph.D. 1 Martine Banzet, M.D. 1 Jacques-André Bazex, M.D. 3 Philippe Lauret, M.D. 4 Olivier Vérola, M.D. 5 Gérard Auclerc, M.D. 1 Peter Harper, M.D. 6 Pierre Banzet, M.D. 7 for the French Group of Research on Malignant Melanoma 1 Service d Oncologie Médicale, Hôpital Pitié-Salpêtrière, Paris, France. 2 Service de Chirurgie, Centre Hospitalier de l Université de Montréal, Montréal, Quebec, Canada. 3 Service de Dermatologie, Hôpital Purpan, Toulouse, France. 4 Service de Dermatologie, Hôpital Charles Nicolle, Rouen, France. 5 Service d Anatomopathologie, Hôpital Saint- Louis, Paris, France. 6 Medical Oncology Department, Guy s and Saint Thomas Hospital, London, United Kingdom. 7 Service de Chirurgie Plastique Reconstructive et Esthétique, Hôpital Saint-Louis, Paris, France. Supported by the Association Pour la Vie-Espoir Contre le Cancer (A.V.E.C.). Dr. Peter Harper is an advisory board member for Lilly, Adventis, Glaxo Smithkline, Bristol-Myers Squibb, Roche, and Johnson & Johnson. Address for reprints: David Khayat, M.D., Ph.D., Department of Medical Oncology, Salpetriere Hospital, 47, Boulevard de l Hopital, Paris, France; Fax: (011) ; david.khayat@psl.ap-hop-paris.fr Received February 15, 2002; revision received February 11, 2002; accepted February 12, BACKGROUND. This study addressed the question of whether limited surgery for primary malignant melanoma with a 2-cm margin is as good as a 5-cm margin. An update of a 16-year follow-up is provided. METHODS. Nine European Centers, over a period of 5 years, prospectively randomized 337 patients with melanoma measuring less than 2.1 mm in thickness to undergo a local excision with either a 2-cm or a 5-cm margin. Three hundred twenty-six patients were eligible for statistical analysis. Excluded from the trial were patients older than 70 years; those with melanomas from the toe, nail, or finger; and those with acral-lentiginous melanoma. A separate randomization was performed to independently test an adjuvant treatment with a nonspecific immunostimulant, isoprinosine, compared with observation. The median follow-up time was 192 months (16 years) for the estimation of survival and disease recurrences. RESULTS. There were 22 tumor recurrences in the 2-cm arm and 33 in the 5-cm arm. The median time to disease recurrence was 43 months and 37.6 months, respectively. The 10-year disease-free survival rates were 85% for the group with a 2-cm margin and 83% for the group with a 5-cm margin. There was no difference in the 10-year overall survival rates (87% vs. 86%). Isoprinosine did not demonstrate any activity in this setting. CONCLUSIONS. The authors concluded that for melanoma less than 2.1-mm thick, a margin of excision of 2 cm is sufficient. A larger margin of 5 cm does not appear to have any impact on either the rate or the time to disease recurrence or on survival. Cancer 2003;97: American Cancer Society. DOI /cncr KEYWORDS: malignant melanoma, surgery, immunotherapy, prognostic factors. The incidence of malignant melanoma is increasing. Therefore, it is important to optimize the surgical management of patients with this tumor. For decades, a wide local excision with a margin as large as 3 5 cm around the lesion was recommended, resulting in significant morbidity. Retrospective and prospective studies have emphasized the importance of tumor thickness in predicting local disease recurrence, 1 3 raising the hypothesis that significantly less mutilating approaches could be sufficient for thin lesions. Two large multicenter prospective trials have evaluated margins in TNM Stage I malignant melanoma. The World Health Organization (WHO) 4 melanoma program studied the effectiveness of a 1-cm margin for thin melanomas ( 1 mm). Balch et al. 5 evaluated 2-cm versus 4-cm margins for 1 4-mm thick primary melanomas. In their multifactorial analysis of prognostic factors, they reported that thickness, the presence of ulceration, and anatomic site were important prognostic factors and 2003 American Cancer Society
2 1942 CANCER April 15, 2003 / Volume 97 / Number 8 that a 2-cm or 4-cm margin demonstrated no statistical difference in overall survival or local disease recurrence. Although incidence of malignant melanoma is increasing, the use of prevention campaigns has resulted in lesions being diagnosed at an earlier stage. 6 8 As a consequence of earlier diagnosis, the number of lesions measuring 2 mm or less in thickness is expected to increase Optimal management of this group of tumors is essential, with a major impact on cosmesis, quality of life, and cost. This study was designed to address the margin of excision (2 cm vs. 5 cm) for primary melanoma measuring 2 mm or less in thickness. A secondary end point of our trial was to evaluate the role of adjuvant immunotherapy using isoprinosine, a nonspecific immunostimulant that has shown promising results in preclinical models. 12 A double randomization study was performed to independently test the two therapeutic interventions (surgical margin and adjuvant isoprinosine). MATERIALS AND METHODS A prospective multicenter randomized clinical trial was initiated in 1981 in nine European centers. Patients younger than 70 years, with a maximum tumor thickness of 2 mm (Breslow 2 mm), were eligible. All patients were Stage I by TNM criteria. Excluded were toe, nail, or finger lesions and melanomas arising from melanosis, lentigo, and acral lesions. Before entry, all patients underwent a clinical examination, chest X-ray, and liver ultrasound. Patients were randomized to either wide (5 cm) or limited (2 cm) excision surgery. All biopsy specimens were reviewed to confirm the tumor thickness and histologic classification. According to the surgical protocol guidelines, the resection was performed within the month of the initial biopsy. Excisions extended down to the muscular fascia. A total resection margin means that, if the tumor primarily was resected with a 2-cm margin, no further resection was performed if the patient was randomized to the limited excision group. By contrast, if the patient was randomized to the 5-cm excision margin group, a complementary resection of at least 3 cm was performed. The reported excision margin is the summarized excision margins for each patient, when available. Lymph node dissections were not performed. A second randomization allocated the patient to either 12 months of adjuvant treatment with isoprinosine or to no adjuvant treatment (Fig. 1). Isoprinosine was used as a pulse immunotherapy, the dose being one tablet (500 mg)/10 kg per day for 5 days every 15 days. Patients characteristics, including FIGURE 1. Randomization of melanoma patients. surgical margins, were balanced between the two groups based on the immunotherapy randomization. Three hundred thirty-seven patients entered the trial with a median follow-up of 192 months (range, months). The cut off date for data collection was December Local disease recurrence was defined as recurrence within 2 cm of the scar. In-transit metastases were defined as disease recurrence between the primary tumor site and the regional lymph nodes. Local or regional tumors that recurred were removed surgically and follow-up medical treatment was not provided. Metastatic tumors were treated with chemotherapy (dacarbazine, fotemustine, or a combination) or with biochemotherapy (a combination of cisplatin, interleukin-2, and interferon-alpha). The survival analysis (overall survival and progression-free survival) was performed using the actuarial Kaplan Meier method and differences between the curves were analyzed using the log rank test. Survival times were calculated from the date of inclusion until death. Time to disease progression was calculated from the date of inclusion to the date of disease progression. All results are quoted as two-sided P values and differences were considered significant if P values were less than The statistical power of this study to detect a 10% difference in survival and recurrence rate was estimated at 70%. The Cox proportional hazards model was used to evaluate prognostic factors and contingency tables were analyzed by an appropriate chisquare test or exact t test. RESULTS Of the 337 patients enrolled, 11 were not eligible (6 were randomized to the narrow excision arm and 5 to the wide excision arm). Exclusion criteria included lesions thicker than 2.0 mm (four patients),
3 Cutaneous Melanoma/Khayat et al TABLE 1 Clinical Characteristics by Randomized Arms (n 326) 2cm(n 161) 5 cm (n 165) Characteristics (n 85) (n 76) Total (n 76) (n 89) Total P value Age (mean) Gender Men (n 122) Women (n 204) Location (missing 16) Head and neck (n 16) Trunk (n 93) Upper extremity (n 68) Lower extremity (n 138) Other (n 5) Clark level of invasion (missing 3) I(n 1) II (n 54) III (n 181) IV (n 80) Histology (missing 1) Superficial spreading (n 281) Nodular (n 41) No class (n 3) Breslow tumor thickness (mm) : treated with isoprinosine; : not treated with isoprinosine. Dubreuilh s melanosis based lesions (three patients), age older than 70 years (one patient), and toe or nail lesions (three patients). Therefore, 326 patients were evaluated. There were 122 men and 204 women. The mean age of the sample was 44 years (standard deviation 13 years). One hundred and sixty-one patients were assigned to limited surgical excision (2 cm) and 165 were assigned to wide local excision (5 cm). Both surgical groups were comparable for gender, age, location of the tumor, Clark level of invasion, histologic type, and tumor thickness (Table 1). After nearly 20 years of follow-up, 40 patients (12%) were lost to follow-up. Another 36 patients had missing information regarding the date of their tumor recurrences. However, their death certificate data were evaluable for survival analysis (17 patients in the limited excision arm and 19 in the wide excision arm). Therefore, 243 patients were evaluable for disease-free survival and 286 patients were evaluable for survival (139 for the 2-cm margin and 147 for the 5-cm margin). Ninety-five and 93 patients were free of disease for the 2-cm and 5-cm margins, respectively (Table 2). Fifty-five patients had disease recurrence after a mean TABLE 2 Tumor Recurrences and Deaths in Each Surgical Arm Follow-up 2cm (n 161) (%) 5cm (n 165) (%) Total (n 326) (%) No tumor recurrence 95 (59) 93 (56.3) 188 (57.6) Tumor recurrences 22 (13.6) 33 (20) 55 (16.8) Death 32 (19.8) 29 (17.5) 61 (18.7) Lost to follow-up 22 (13.6) 18 (10.9) 40 (12.3) disease-free interval of 33 months (range, months). Of these 55, had local tumor recurrences, 38 had distant or regional lymph node involvement, and 12 were unknown. Twenty-two patients had tumor recurrence in the 2-cm margin arm versus 33 in the 5-cm margin group. Local tumor recurrence occurred in four patients (Breslow thickness: 0.95 mm, 1.05 mm, 1.22 mm, and 1.5 mm) who had wide excision and in only one patient with a narrow excision (Breslow thickness: 2 mm). The type of tumor recurrences and surgery performed were independent on statistical analysis (P
4 1944 CANCER April 15, 2003 / Volume 97 / Number 8 TABLE 3 Types of Tumor Recurrences for Each Surgical Arm Type or recurrence 2cm (n 161) (%) 5cm (n 165) (%) Total (n 326) (%) Local Breslow thickness 1mm 0 1 Breslow thickness 1mm 1 3 Distant 4 (2.5) 10 (6.1) 14 (4.3) Regional lymph node 13 (8.1) 11 (6.7) 24 (7.4) Unknown 4 (2.5) 8 (4.8) 12 (3.7) Total 22 (13.6) 33 (20) 55 (16.9) FIGURE 3. Disease-free survival according to the extent of surgery. Statistical analysis was performed using the log-rank test (P 0.83). FIGURE 2. Overall survival according to the extent of surgery. Statistical analysis was performed using the log-rank test (P 0.56) 0.22) (Table 3). The median time to tumor recurrence was 42.1 months (range, months). The disease-free survival rates at 10 years were 85% in the 2-cm arm and 83% in the 5-cm arm. This difference was not significant (P 0.83) (Fig. 2). On follow-up, 31 deaths were related to melanoma and 23 deaths were unrelated to melanoma. Seven deaths for which the cause was not specified were evaluated as related. Survival was not modified by surgical margin. Overall survival rates at 10 years were 87% for the 2-cm excision and 86% for the 5-cm excision groups (P 0.56) (Fig. 3). Clinical and pathologic prognostic factors were evaluated using previously defined factors. 1 3 In univariate analysis, the number of tumor recurrences was higher according to tumor thickness and male gender (P 0.03 and P 0.01, respectively; Fig. 4 and 5). Survival was influenced by the same factors (P 0.03 and P 0.02, respectively). Other a priori known prognostic factors (e.g., location, histologic type, or age) FIGURE 4. Disease-free survival according to gender. Statistical analysis was performed using the log-rank test (P 0.01). did not appear to statistically influence either overall or disease-free survival. We evaluated the risk of death and tumor recurrence among patients with 1 2-mm thick lesions compared with patients with less than 1-mm thick lesions. A univariate Cox regression model showed that the relative risk of death was 3.6 for patients with melanomas 1 2-mm thick compared with those with lesions less than 1-mm thick (P 0.001; 95% confidence interval [CI], ). The risk of tumor recurrence estimated at 4.0 was also significantly higher in that subgroup (P ; 95% CI, ). The outcome (tumor recurrence, death) was not statistically different for these two subgroups based on the excision margin. The second randomization to receive or not to
5 Cutaneous Melanoma/Khayat et al FIGURE 5. Disease-free survival according to tumor thickness (P 0.032). receive isoprinosine did not appear to affect the outcome of these patients. The median survival periods with or without the drug were 190 months and 192 months respectively (P 0.9) and the disease-free survival periods were months and months, respectively, (P 0.89). No statistically significant influence of this adjuvant immunotherapy was noted on any subgroup analysis (e.g., extent of surgery, location, and thickness). DISCUSSION The WHO 4 melanoma program studied 612 patients with malignant melanoma of 2 mm or less in thickness. The mean follow-up was 90 months. Veronesi et al. 4 concluded that a 1-cm radial margin for thin melanoma ( 1 mm) was as safe as a 3-cm margin or more. In patients with lesions thicker than 1 mm who underwent a 1-cm excision margin, 4 of 307 lesions metastasized. In a prospective study of 486 patients with a median follow-up of 6 years, Balch et al. 5 showed that a 2-cm margin for lesions 1 4-mm thick was as good as a 4-cm margin. There were two local tumor recurrences in the 2-cm margin group, both with a thickness of 2.1 mm or less. There were three local tumor recurrences in the 4-cm margin group, all with thicknesses greater than 2.3 mm. Balch et al. concluded that a 2-cm or 4-cm margin demonstrated no statistical difference with regard to overall survival and local tumor recurrence. However, for lesions measuring less than 2 mm, some questions remained regarding long-term prognosis. In accordance with other studies, we found that in Stage I melanoma patients, both gender and tumor thickness (Breslow) were prognostically significant. The Swedish Melanoma Study group published a long-term follow-up (median follow-up for survival of 11 years) of a trial of 989 patients with a tumor thickness of mm. It found no advantage of performing a 5-cm margin over a 2-cm margin. 13 The prognostic factor analysis in that study did not show Clark level to be important in thin melanomas. Veronesi et al. 4 compared a 2-cm margin with a 1-cm margin and demonstrated no survival difference. The WHO trial for lesions measuring mm reported a slightly higher risk of local tumor recurrence in the 1-cm cohort without any apparent impact on survival. They confirmed that lesions 1 mm or smaller have better overall and disease-free survival rates compared with lesions of 1 2 mm. Our study, which compared a 2-cm margin with a 5-cm margin, did not show a difference in local tumor recurrence rates, disease-free survival, or overall survival for lesions measuring less than 2 mm in thickness. For lesions measuring less than 1 mm, a more limited excision may be sufficient. 2 In 1987, isoprinosine was shown in vitro to immunostimulate natural killer cells against melanoma cells. We, therefore, prospectively randomized the use of isoprinosine in our trial. The trend toward a significant clinical benefit related to the use of adjuvant isoprenosine was found to vanish completely with longer follow-up. We conclude that an excision margin larger than 2 cm for lesions of less than 2 mm depth is unnecessary. For lesions measuring less than 1 mm, a more conservative 1-cm margin may be used. Systemic adjuvant isoprinosine did not prevent tumor recurrence or death in patients with thin melanoma and in our opinion should not be used in that setting. REFERENCES 1. Balch CM, Murad TM, Soong S-J, et al. A multifactorial analysis of melanoma: prognostic histopathological features comparing Clark s and Breslow s staging methods. Ann Surg. 1978;188: Balch CM, Soong S-J, Milton GW, et al. A comparison of prognostic factors and surgical results in 1786 patients with localized (Stage I) melanoma treated in Alabama, USA and New South Wales, Australia. Ann Surg. 1982;196: Balch CM, Murad TM, Soong S-J, et al. Tumor thickness as a guide to surgical management of clinical Stage I melanoma patients. Cancer. 1979;43: Veronesi U, Cascinelli N. Narrow excision (1 cm margin) a safe procedure for thin cutaneous melanoma. Arch Surg. 1991;126: Balch CM, Urist MM, Constantine P, et al. Efficacy of a2cm surgical margin for intermediate thickness melanomas (1 to 4 mm). Results of a multi-institutional randomized surgical trial. Ann Surg. 1993;218: Armstrong BK, Kricker A. Cutaneous melanoma. Cancer Surv. 1994;19:
6 1946 CANCER April 15, 2003 / Volume 97 / Number 8 7. Elwood JM. Recent developments in melanoma epidemiology. Melanoma Res. 1993;3: Mackie RM, Hole D. Audit of public education campaign to encourage earlier detection of malignant melanoma. BMJ. 1992;304: Mackie RM, Hunter JAA, Blessing K, et al. Changing tumor thickness in melanomas in Scotland Melanoma Res. 1993;3(Suppl 1): Burton RC, Armstrong BK. Recent incidence trends imply a non-metastasizing form of invasive melanoma. Melanoma Res. 1994;4: Burton RC. Analysis of public education and the implications with regard to nonprogressive thin melanomas. Curr Opin Oncol. 1995;7: Pompidou A, Soubrane C, Cour V, Telvi L, Meunier C, Jacquillat C. Immunological effects of isoprinosine as a pulse immunotherapy in melanoma and ARC patients. Cancer Detect Prev. 1987;(Suppl 1): Cohn-Cedermark G, Rutqvist LE, Andersoson R, et al. Long term results of a randomized study by the Swedish Melanoma Study Group on 2-cm versus 5-cm resection margins for patients with cutaneous melanoma with a tumor thickness of mm. Cancer. 2000:89:
Malignant Melanoma in Turkey: A Single Institution s Experience on 475 Cases
Malignant Melanoma in Turkey: A Single Institution s Experience on 475 Cases Faruk Tas, Sidika Kurul, Hakan Camlica and Erkan Topuz Institute of Oncology, Istanbul University, Istanbul, Turkey Received
More informationPatient age and cutaneous malignant melanoma: Elderly patients are likely to have more aggressive histological features and poorer survival
MOLECULAR AND CLINICAL ONCOLOGY 7: 1083-1088, 2017 Patient age and cutaneous malignant melanoma: Elderly patients are likely to have more aggressive histological features and poorer survival FARUK TAS
More informationSurgical Issues in Melanoma
Surgical Issues in Melanoma Mark B. Faries, MD, FACS Director, Donald L. Morton Melanoma Research Program Director, Surgical Oncology Training Program Professor of Surgery John Wayne Cancer Institute Surgical
More informationORIGINAL ARTICLE. Clinical Node-Negative Thick Melanoma
ORIGINAL ARTICLE Clinical Node-Negative Thick Melanoma George I. Salti, MD; Ashwin Kansagra, MD; Michael A. Warso, MD; Salve G. Ronan, MD ; Tapas K. Das Gupta, MD, PhD, DSc Background: Patients with T4
More informationRebecca Vogel, PGY-4 March 5, 2012
Rebecca Vogel, PGY-4 March 5, 2012 Historical Perspective Changes In The Staging System Studies That Started The Talk Where We Go From Here Cutaneous melanoma has become an increasingly growing problem,
More informationKatsuhiro Yamada, Natsuko Noguti, Masaaki Tsuda, Hazime Nagato, Naoko Hasunuma, Yoshihiro Umebayashi and Motomu Manabe
Akita J Med 36 : 45-52, 2009 45 Katsuhiro Yamada, Natsuko Noguti, Masaaki Tsuda, Hazime Nagato, Naoko Hasunuma, Yoshihiro Umebayashi and Motomu Manabe (Received 22 December 2008, Accepted 15 January 2009)
More informationClinical and Pathological Features of Cutaneous Malignant Melanoma: A Retrospective Analysis of 124 Japanese Patients
Clinical and Pathological Features of Cutaneous Malignant Melanoma: A Retrospective Analysis of 24 Japanese Patients Yoshie Kuno, Kazuyuki Ishihara, Naoya Yamazaki and Kiyoshi Mukai 2 'Dermatology Division
More informationClinical Study Mucosal Melanoma in the Head and Neck Region: Different Clinical Features and Same Outcome to Cutaneous Melanoma
ISRN Dermatology Volume 2013, Article ID 586915, 5 pages http://dx.doi.org/10.1155/2013/586915 Clinical Study Mucosal Melanoma in the Head and Neck Region: Different Clinical Features and Same Outcome
More informationDesmoplastic Melanoma: Surgical Management and Adjuvant Therapy
Desmoplastic Melanoma: Surgical Management and Adjuvant Therapy Dale Han, MD Assistant Professor Department of Surgery Section of Surgical Oncology No disclosures Background Desmoplastic melanoma (DM)
More informationPolypoid Melanoma, A Virulent Variant of the Nodular Growth Pattern
Polypoid Melanoma, A Virulent Variant of the Nodular Growth Pattern ELIZABETH A. MANCI, M.D., CHARLES M. BALCH, M.D..TARIQ M. MURAD, M.D., PH.D., AND SENG/JAW SOONG, PH.D. Manci, Elizabeth A., Balch, Charles
More informationProtocol applies to melanoma of cutaneous surfaces only.
Melanoma of the Skin Protocol applies to melanoma of cutaneous surfaces only. Procedures Biopsy (No Accompanying Checklist) Excision Re-excision Protocol revision date: January 2005 Based on AJCC/UICC
More informationMelanoma Quality Reporting
Melanoma Quality Reporting September 1, 2013 December 31, 2016 Laurence McCahill, MD Surgical Oncologist Metro Health Surgical Oncology Metro Health Professional Building 2122 Health Drive SW Wyoming,
More informationTHE NEW ZEALAND MEDICAL JOURNAL
THE NEW ZEALAND MEDICAL JOURNAL Journal of the New Zealand Medical Association The incidence and thickness of cutaneous malignant melanoma in New Zealand 1994 2004 Ann Richardson, Lynn Fletcher, Mary Jane
More informationCancer Registry Report. Cancer Focus: Melanoma
Cancer Registry Report Cancer Focus: Melanoma In 2005, nearly 60,000 patients were diagnosed with melanoma, resulting in about 7800 deaths Fortunately, melanoma is often diagnosed in an early stage when
More informationEpidemiology DATA AND METHODS
British Journal of Cancer () 9, 91 9 All rights reserved 7 9/ $3. www.bjcancer.com Recent trends in cutaneous malignant melanoma in the Yorkshire region of England; incidence, mortality and survival in
More informationJohan Lyth, J Hansson, C Ingvar, E Mansson-Brahme, P Naredi, U Stierner, G Wagenius and C Lindholm. Linköping University Post Print
Prognostic subclassifications of T1 cutaneous melanomas based on ulceration, tumour thickness and Clark s level of invasion: results of a population-based study from the Swedish Melanoma Register Johan
More informationUpdates on Melanoma: Are You Following the Latest Guidelines of Care? Jerry Brewer, MD
Updates on Melanoma: Are You Following the Latest Guidelines of Care? Jerry Brewer, MD Disclosure Statement Update on Melanoma Are You Following the Latest Guidelines of Care? I, Jerry D. Brewer, MD, do
More informationAmelanotic melanoma of the skin detailed review of the problem
of the skin detailed review of the problem Strahil Strashilov 1, Veselin Kirov 2, Angel Yordanov 3, Yoana Simeonova 4 and Miroslava Mihailova 5 1. Department of Plastic Restorative, Reconstructive and
More informationClinical Pathological Conference. Malignant Melanoma of the Vulva
Clinical Pathological Conference Malignant Melanoma of the Vulva History F/48 Chinese Married Para 1 Presented in September 2004 Vulval mass for 2 months Associated with watery and blood stained discharge
More informationCutaneous Melanoma: Epidemiology (USA) The Sentinel Node in Head and Neck Melanoma. Cutaneous Melanoma: Epidemiology (USA)
The Sentinel Node in Head and Neck Melanoma Cutaneous Melanoma: Epidemiology (USA) 6 th leading cause of cancer among men and women 68,720 new cases of invasive melanoma in 2009 8,650 deaths from melanoma
More informationMelanoma-Back to Basics I Thought I Knew Ya! Paul K. Shitabata, M.D. Dermatopathologist APMG
Melanoma-Back to Basics I Thought I Knew Ya! Paul K. Shitabata, M.D. Dermatopathologist APMG At tumor board, a surgeon insists that all level II melanomas are invasive since they have broken through the
More informationTalk to Your Doctor. Fact Sheet
Talk to Your Doctor Hearing the words you have skin cancer is overwhelming and would leave anyone with a lot of questions. If you have been diagnosed with Stage I or II cutaneous melanoma with no apparent
More informationPrognostic Variables and Surgical Management of Foot Melanoma: Review of a 25-Year Institutional Experience
Virginia Commonwealth University VCU Scholars Compass Surgery Publications Dept. of Surgery 11 Prognostic Variables and Surgical Management of Foot Melanoma: Review of a 5-Year Institutional Experience
More informationThis is a repository copy of Long term follow up of survival in a randomised trial of wide or narrow excision margins in high risk primary melanoma..
This is a repository copy of Long term follow up of survival in a randomised trial of wide or narrow excision margins in high risk primary melanoma.. White Rose Research Online URL for this paper: http://eprints.whiterose.ac.uk/93871/
More informationCase Scenario 1 Worksheet. Primary Site C44.4 Morphology 8743/3 Laterality 0 Stage/ Prognostic Factors
CASE SCENARIO 1 9/10/13 HISTORY: Patient is a 67-year-old white male and presents with lesion located 4-5cm above his right ear. The lesion has been present for years. No lymphadenopathy. 9/10/13 anterior
More informationImpact of Prognostic Factors
Melanoma Prognostic Factors: where we started, where are we going? Impact of Prognostic Factors Staging Management Surgical intervention Adjuvant treatment Suraj Venna, MD Assistant Clinical Professor,
More informationDr. Brent Doolan, BSc MBBS MPH
Impact of partial biopsies on the need for complete excisional surgery in the management of cutaneous melanomas: A multi-centre review Dr. Brent Doolan, BSc MBBS MPH Peter MacCallum Cancer Centre, Melbourne
More information1 Cancer Council Queensland, Brisbane, Queensland, Australia.
Title: Diagnosis of an additional in situ does not influence survival for patients with a single invasive : A registry-based follow-up study Authors: Danny R Youlden1, Kiarash Khosrotehrani2, Adele C Green3,4,
More informationInvasive Cutaneous Malignant Melanoma in Sweden, A Prospective, Population-Based Study of Survival and Prognostic Factors
2067 Invasive Cutaneous Malignant Melanoma in Sweden, 1990 1999 A Prospective, Population-Based Study of Survival and Prognostic Factors Christer Lindholm, M.D., Ph.D. 1 Ronny Andersson, M.D. 2 * Monika
More informationNational Horizon Scanning Centre. Ipilimumab (MDX-010) for unresectable stage III or IV metastatic melanoma - first or second line treatment
Ipilimumab (MDX-010) for unresectable stage III or IV metastatic melanoma - first or second line treatment April 2008 This technology summary is based on information available at the time of research and
More informationImmunotherapy in the Adjuvant Setting for Melanoma: What You Need to Know
Immunotherapy in the Adjuvant Setting for Melanoma: What You Need to Know Jeffrey Weber, MD, PhD Laura and Isaac Perlmutter Cancer Center NYU Langone Medical Center New York, New York What Is the Current
More informationIndex. Note: Page numbers of article titles are in boldface type. A Age as factor in melanoma, Anorectal melanoma RT for, 1035
Index Note: Page numbers of article titles are in boldface type. A Age as factor in melanoma, 947 948 Anorectal melanoma RT for, 1035 B Bacille Calmette-Guerin (BCG) in melanoma, 1008 BCG. See Bacille
More informationClinical Practice Guidelines
Clinical Practice Guidelines Clinical Practice Guidelines for Melanoma Douglas Reintgen, MD, et al H. Lee Moffitt Cancer Center & Research Institute These clinical practice guidelines for melanoma have
More informationMalignant Melanoma Early Stage. A guide for patients
This melanoma patient brochure is designed to help educate melanoma patients and their caregivers. It was developed under the guidance of Dr. Michael Smylie, Professor, Department of Oncology, University
More informationResearch Article Melanoma in Buckinghamshire: Data from the Inception of the Skin Cancer Multidisciplinary Team
Skin Cancer Volume 2013, Article ID 843282, 6 pages http://dx.doi.org/10.1155/2013/843282 Research Article Melanoma in Buckinghamshire: Data from the Inception of the Skin Cancer Multidisciplinary Team
More information1. Written information to patient /GP: fax ASAP to GP & offer copy of consultation letter.
Skin Cancer follow up guidelines If NEW serious diagnosis given: 1. Written information to patient /GP: fax ASAP to GP & offer copy of consultation letter. 2. Free prescription information details. 3.
More informationNEW SURGICAL APPROACHES TO MELANOMA THERAPY
NEW SURGICAL APPROACHES TO MELANOMA THERAPY Melanoma 2003: New Insights Into Therapy & Treatment Douglas L. Fraker, M.D. University of Pennsylvania Surgical Treatment of Melanoma Primary resection margins
More informationPeritoneal Involvement in Stage II Colon Cancer
Anatomic Pathology / PERITONEAL INVOLVEMENT IN STAGE II COLON CANCER Peritoneal Involvement in Stage II Colon Cancer A.M. Lennon, MB, MRCPI, H.E. Mulcahy, MD, MRCPI, J.M.P. Hyland, MCh, FRCS, FRCSI, C.
More informationYou Are Going to Cut How Much Skin? Locoregional Surgical Treatment. Justin Rivard MD, MSc, FRCSC September 21, 2018
You Are Going to Cut How Much Skin? Locoregional Surgical Treatment Justin Rivard MD, MSc, FRCSC September 21, 2018 Presenter Disclosure Faculty/Speaker: Justin Rivard Relationships with financial sponsors:
More informationMetastatic Melanoma. Cynthia Kwong February 16, 2017 SUNY Downstate Medical Center Department of Surgery Grand Rounds
Metastatic Melanoma Cynthia Kwong February 16, 2017 SUNY Downstate Medical Center Department of Surgery Grand Rounds Case Presentation 77 year old male with previous history of scalp melanoma and thyroid
More informationORIGINAL ARTICLE PROGNOSTIC IMPLICATION OF SENTINEL LYMPH NODE BIOPSY IN CUTANEOUS HEAD AND NECK MELANOMA
ORIGINAL ARTICLE PROGNOSTIC IMPLICATION OF SENTINEL LYMPH NODE BIOPSY IN CUTANEOUS HEAD AND NECK MELANOMA Benjamin E. Saltman, MD, 1 Ian Ganly, MD, 2 Snehal G. Patel, MD, 2 Daniel G. Coit, MD, 3 Mary Sue
More informationBreslow Thickness and Clark Level Evaluation in Albanian Cutaneous Melanoma
Research DOI: 10.6003/jtad.16104a2 Breslow Thickness and Clark Level Evaluation in Albanian Cutaneous Melanoma Daniela Xhemalaj, MD, Mehdi Alimehmeti, MD, Susan Oupadia, MD, Majlinda Ikonomi, MD, Leart
More informationSkin lesions suspicious for melanoma: New Zealand excision margin guidelines in practice
Skin lesions suspicious for melanoma: excision margin guidelines in practice Tess Brian MBBS; 1 Michael B. Jameson MBChB, FRACP, FRCP, PhD 2,3 1 Department of Plastic and Reconstructive Surgery, Waikato
More informationQuality ID #397: Melanoma Reporting National Quality Strategy Domain: Communication and Care Coordination
Quality ID #397: Melanoma Reporting National Quality Strategy Domain: Communication and Care Coordination 2018 OPTIONS FOR INDIVIDUAL MEASURES: CLAIMS ONLY MEASURE TYPE: Outcome DESCRIPTION: Pathology
More informationAn Overview of Melanoma. Harriet Kluger, M.D. Associate Professor Section of Medical Oncology Yale Cancer Center
An Overview of Melanoma Harriet Kluger, M.D. Associate Professor Section of Medical Oncology Yale Cancer Center Melanoma Statistics Median age at presentation 45-55 55 years Incidence: 2003 54,200 cases
More informationMelanoma Case Scenario 1
Melanoma Case Scenario 1 History and physical 11/5/16 Patient is a single, 48-year-old male in good health who presented to his primary physician for a yearly physical exam during which a 3.4 x 2.8 x 1.5
More informationTopics for Discussion. Malignant Melanoma. Surgical Treatment. Current Treatment of Cutaneous Melanoma 5/17/2013. Lymph Regional nodes:
Topics for Discussion What is a sentinel lymph node (SLN)? Utility of sentinel lymph biopsies: therapeutic or staging? Current Treatment of Cutaneous Melanoma Carlos Corvera, M.D. Associate Professor of
More informationWorld Articles of Ear, Nose and Throat Page 1
World Articles of Ear, Nose and Throat ---------------------Page 1 Primary Malignant Melanoma of the Tongue: A Case Report Authors: Nanayakkara PR*, Arudchelvam JD** Ariyaratne JC*, Mendis K*, Jayasekera
More information1
www.clinicaloncology.com.ua 1 Prognostic factors of appearing micrometastases in sentinel lymph nodes in skin melanoma M.N.Kukushkina, S.I.Korovin, O.I.Solodyannikova, G.G.Sukach, A.Yu.Palivets, A.N.Potorocha,
More informationSentinel Lymph Node Status is the Most Important Prognostic Factor in Patients With Melanoma of the Scalp
The Laryngoscope VC 2013 The American Laryngological, Rhinological and Otological Society, Inc. Sentinel Lymph Node Status is the Most Important Prognostic Factor in Patients With Melanoma of the Scalp
More informationNIH Public Access Author Manuscript J Surg Oncol. Author manuscript; available in PMC 2012 August 1.
NIH Public Access Author Manuscript Published in final edited form as: J Surg Oncol. 2011 August 1; 104(2): 111 115. doi:10.1002/jso.21903. Does metastasectomy improve survival in patients with Stage IV
More informationMelanoma Case Scenario 1
Melanoma Case Scenario 1 History and physical 11/5/16 Patient is a single, 48-year-old male in good health who presented to his primary physician for a yearly physical exam during which a 3.4 x 2.8 x 1.5
More informationDesmoplastic Melanoma: Clinical Behavior and Management Implications
Desmoplastic Melanoma: Clinical Behavior and Management Implications Collier S. Pace, MD, a Jyoti P. Kapil, MD, b Luke G. Wolfe, MS, c Brian J. Kaplan, MD, c and James P. Neifeld, MD c a Division of Plastic
More informationMelanoma of the Skin INTRODUCTION SUMMARY OF CHANGES
24 Melanoma of the Skin C44.0 Skin of lip, NOS C44.1 Eyelid C44.2 External ear C44.3 Skin of other and unspecified parts of face C44.4 Skin of scalp and neck C44.5 Skin of trunk C44.6 Skin of upper limb
More informationIs There a Benefit to Sentinel Lymph Node Biopsy in Patients With T4 Melanoma?
Is There a Benefit to Sentinel Lymph Node Biopsy in atients With T4 Melanoma? Csaba Gajdos, MD 1 ; Kent A. Griffith, MH, MS 2 ; Sandra L. Wong, MD 1 ; Timothy M. Johnson, MD 1,3 ; Alfred E. Chang, MD 1
More informationMelanoma of the Skin
24 Melanoma of the Skin C44.0 Skin of lip, NOS C44.1 Eyelid C44.2 External ear C44.3 Skin of other and unspecified parts of face C44.4 Skin of scalp and neck C44.5 Skin of trunk C44. Skin of upper limb
More informationPAPER. Prognostic Information From Sentinel Lymph Node Biopsy in Patients With Thick Melanoma
PAPER Prognostic Information From Sentinel Lymph Node Biopsy in Patients With Thick Melanoma Charles R. Scoggins, MD, MBA; Adrianne L. Bowen, MD; Robert C. Martin II, MD, PhD; Michael J. Edwards, MD; Douglas
More informationRadiotherapy and Conservative Surgery For Merkel Cell Carcinoma - The British Columbia Cancer Agency Experience
Radiotherapy and Conservative Surgery For Merkel Cell Carcinoma - The British Columbia Cancer Agency Experience Poster No.: RO-0003 Congress: RANZCR FRO 2012 Type: Scientific Exhibit Authors: C. Harrington,
More informationMorphological characteristics of the primary tumor and micrometastases in sentinel lymph nodes as a predictor of melanoma progression
Morphological characteristics of the primary tumor and micrometastases in sentinel lymph nodes as a predictor of melanoma progression M.N. Kukushkina, S.I. Korovin, O.I. Solodyannikova, G.G. Sukach, A.Yu.
More informationRacial differences in six major subtypes of melanoma: descriptive epidemiology
Wang et al. BMC Cancer (2016) 16:691 DOI 10.1186/s12885-016-2747-6 RESEARCH ARTICLE Racial differences in six major subtypes of melanoma: descriptive epidemiology Yu Wang 1, Yinjun Zhao 2 and Shuangge
More informationAssociation of wait times to surgical, medical and radiation therapies with overall survival in Ontarians with melanoma
Association of wait times to surgical, medical and radiation therapies with overall survival in Ontarians with melanoma Alyson Crawford Thesis submitted to the Faculty of Graduate and Postdoctoral Studies
More informationMelanoma. Kaushik Mukherjee MD A. Scott Pearson MD
Melanoma Kaushik Mukherjee MD A. Scott Pearson MD Disclosures You still have to study Not all inclusive No Western blots Extensive use of Google Image Search and Sabiston Melanoma Basics 8 th most common
More informationMolecular Enhancement of Sentinel Node Evaluation
Cochran Illustrations 060104 Molecular Enhancement of Sentinel Node Evaluation Alistair Cochran, MD and Rong Huang MD Departments of Pathology and Laboratory Medicine and Surgery, David Geffen School of
More informationUniversity of Groningen
University of Groningen Nodular Histologic Subtype and Ulceration are Tumor Factors Associated with High Risk of Recurrence in Sentinel Node-Negative Melanoma Patients Faut, Marloes; Wevers, Kevin; van
More informationImplications of Progesterone Receptor Status for the Biology and Prognosis of Breast Cancers
日大医誌 75 (1): 10 15 (2016) 10 Original Article Implications of Progesterone Receptor Status for the Biology and Prognosis of Breast Cancers Naotaka Uchida 1), Yasuki Matsui 1), Takeshi Notsu 1) and Manabu
More informationORIGINAL ARTICLE. Predicting the Prognosis of Oral Squamous Cell Carcinoma After First Recurrence
ORIGINAL ARTICLE Predicting the Prognosis of Oral Squamous Cell Carcinoma After First Recurrence Michael D. Kernohan, FDSRCS, FRCS, MSc; Jonathan R. Clark, FRACS; Kan Gao, BEng; Ardalan Ebrahimi, FRACS;
More informationORIGINAL ARTICLE Cutaneous malignant melanoma: clinical and histopathological review of cases in a Malaysian tertiary referral centre
Malaysian J Pathol 202; (2) : 97 0 ORIGINAL ARTICLE Cutaneous malignant melanoma: clinical and histopathological review of cases in a Malaysian tertiary referral centre Jayalakshmi PAILOOR, Kein-Seong
More informationEpithelial Cancer- NMSC & Melanoma
Epithelial Cancer- NMSC & Melanoma David Chin MB, BCh, BAO, LRCP, LRCS (Ireland) MCh(MD), PhD (UQ), FRCS, FRACS (Plast) Plastic & Reconstructive Surgeon Visiting Scientist Melanoma Genomic Group & Drug
More informationTherapeutic Lymph Node Dissection in Melanoma: Different Prognosis for Different Macrometastasis Sites?
Ann Surg Oncol (01) 19:91 91 DOI.14/s44-01-401- ORIGINAL ARTICLE MELANOMAS Therapeutic Lymph Node Dissection in Melanoma: Different Prognosis for Different Macrometastasis Sites? K. P. Wevers, MD, E. Bastiaannet,
More informationAfter primary tumor treatment, 30% of patients with malignant
ESTS METASTASECTOMY SUPPLEMENT Alberto Oliaro, MD, Pier L. Filosso, MD, Maria C. Bruna, MD, Claudio Mossetti, MD, and Enrico Ruffini, MD Abstract: After primary tumor treatment, 30% of patients with malignant
More informationMeasure #397: Melanoma Reporting National Quality Strategy Domain: Communication and Care Coordination
Measure #397: Melanoma Reporting National Quality Strategy Domain: Communication and Care Coordination 2017 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY MEASURE TYPE: Outcome DESCRIPTION: Pathology reports
More informationWHAT DOES THE PATHOLOGY REPORT MEAN?
Melanoma WHAT IS MELANOMA? Melanoma is a type of cancer that affects cells called melanocytes. These cells are found mainly in skin but also in the lining of other areas such as nose and rectum, and also
More informationNodal staging in localized melanoma. The experience of the Brescia Melanoma Unit
The British Association of Plastic Surgeons (2003) 56, 534 539 Nodal staging in localized melanoma. The experience of the Brescia Melanoma Unit Giorgio Manca a, *, Fabio Facchetti b, Claudio Pizzocaro
More informationTranslating Evidence into Practice: Primary Cutaneous Melanoma Guidelines. Sentinel Lymph Node Biopsy
American Academy of Dermatology 2018 Annual Meeting San Diego, CA, February 17, 2018 Translating Evidence into Practice: Primary Cutaneous Melanoma Guidelines. Sentinel Lymph Node Biopsy Christopher Bichakjian,
More informationMelanoma Surgery Update James R. Ouellette, DO FACS Premier Health Cancer Institute Wright State University Chief, Surgical Oncology Division
Melanoma Surgery Update 2018 James R. Ouellette, DO FACS Premier Health Cancer Institute Wright State University Chief, Surgical Oncology Division Surgery for Melanoma Mainstay of treatment for potentially
More informationCharacteristics and Treatment of Cutaneous Melanoma of the Foot
Characteristics and Treatment of Cutaneous Melanoma of the Foot Kyung Wook Nam, Yong Chan Bae,, Soo Bong Nam, Joo Hyung Kim, Hoon Soo Kim, Young Jin Choi Department of Plastic and Reconstructive Surgery,
More informationLong term survival study of de-novo metastatic breast cancers with or without primary tumor resection
Long term survival study of de-novo metastatic breast cancers with or without primary tumor resection Dr. Michael Co Division of Breast Surgery Queen Mary Hospital The University of Hong Kong Conflicts
More informationSKIN CANCER. Most common cancer diagnosis 40% of all cancers
SKIN CANCER Most common cancer diagnosis 40% of all cancers OBJECTIVES Review common and uncommon cancers of the skin. Special emphasis on melanoma and dysplastic nevus Review pathology/tnm/staging, which
More informationCitation for published version (APA): Francken, A. B. (2007). Primary and metastatic melanoma: aspects of follow-up and staging s.n.
University of Groningen Primary and metastatic melanoma Francken, Anne Brecht IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check
More informationSentinel Lymph Node Biopsies in Cutaneous Melanoma: A systematic review of the literature. Sasha Jenkins
Sentinel Lymph Node Biopsies in Cutaneous Melanoma: A systematic review of the literature By Sasha Jenkins A Master s Paper submitted to the faculty of the University of North Carolina at Chapel Hill in
More informationCombined chemotherapy and Radiotherapy for Patients with Breast Cancer and Extensive Nodal Involvement.
Combined chemotherapy and Radiotherapy for Patients with Breast Cancer and Extensive Nodal Involvement. Ung O, Langlands A, Barraclough B, Boyages J. J Clin Oncology 13(2) : 435-443, Feb 1995 STUDY DESIGN
More informationPrimary Cutaneous Melanoma Pathology Reporting Proforma DD MM YYYY. *Tumour site. *Specimen laterality. *Specimen type
Primary Cutaneous Melanoma Pathology Reporting Proforma Includes the International Collaboration on Cancer reporting dataset denoted by * Family name Given name(s) Date of birth DD MM YYYY Sex Male Female
More informationPoor Outcomes in Head and Neck Non-Melanoma Cutaneous Carcinomas
10 The Open Otorhinolaryngology Journal, 2011, 5, 10-14 Open Access Poor Outcomes in Head and Neck Non-Melanoma Cutaneous Carcinomas Kevin C. Huoh and Steven J. Wang * Head and Neck Surgery and Oncology,
More informationLymph node ratio is an important and independent prognostic factor for patients with stage III melanoma.
Thomas Jefferson University Jefferson Digital Commons Department of Surgery Faculty Papers Department of Surgery 1-1-2012 Lymph node ratio is an important and independent prognostic factor for patients
More informationControversies and Questions in the Surgical Treatment of Melanoma
Controversies and Questions in the Surgical Treatment of Melanoma Giorgos C. Karakousis, M.D. Assistant Professor of Surgery Division of Endocrine and Oncologic Surgery University of Pennsylvania School
More informationClinicopathological Factors Affecting Distant Metastasis Following Loco-Regional Recurrence of breast cancer. Cheol Min Kang 2018/04/05
Abstract No.: ABS-0075 Clinicopathological Factors Affecting Distant Metastasis Following Loco-Regional Recurrence of breast cancer 2018/04/05 Cheol Min Kang Department of surgery, University of Ulsan
More informationSpringer Healthcare. Staging and Diagnosing Cutaneous Melanoma. Concise Reference. Dirk Schadendorf, Corinna Kochs, Elisabeth Livingstone
Concise Reference Staging and Diagnosing Cutaneous Melanoma Dirk Schadendorf, Corinna Kochs, Elisabeth Livingstone Extracted from Handbook of Cutaneous Melanoma: A Guide to Diagnosis and Treatment Published
More informationDelayed adjuvant tamoxifen: Ten-year results of a collaborative randomized controlled trial in early breast cancer (TAM-02 trial)
Annals of Oncology 11: 515-519, 2000. 2000 Kluwer Academic Publishers. Printed in the Netherlands. Original article Delayed adjuvant tamoxifen: Ten-year results of a collaborative randomized controlled
More information23/04/2015. Recent advances in Melanoma and Non Melanoma Skin Cancer
Recent advances in and Non Skin Cancer Rodney Sinclair Professor of Dermatology University of Melbourne & Epworth Hospital 86.5% increase 120% increase 37.5% increase 1 To ascertain incidence of NMSC De
More informationPrognostic Significance of Grading and Staging Systems using MIB-1 Score in Adult Patients with Soft Tissue Sarcoma of the Extremities and Trunk
843 Prognostic Significance of Grading and Staging Systems using MIB-1 Score in Adult Patients with Soft Tissue Sarcoma of the Extremities and Trunk Tadashi Hasegawa, M.D. 1 Seiichiro Yamamoto, Ph.D. 2
More information12. Malignant Melanoma of Skin
KEY FACTS 12. Malignant Melanoma of Skin ICD-9 172 On average 160 melanomas of the skin were registered per year. Twice as common in females than in males. Higher than expected numbers in Southern Board
More informationMelanoma Underwriting Presented at 2018 AHOU Conference. Hank George FALU
Melanoma Underwriting Presented at 2018 AHOU Conference Hank George FALU MELANOMA EPIDEMIOLOGY 70-80,000 American cases annually Majority are in situ or thin > 20% are diagnosed age 45 8-9,000 melanoma
More informationInteresting Case Series. Desmoplastic Melanoma
Interesting Case Series Desmoplastic Melanoma Anthony Maurice Kordahi, MD, Joshua B. Elston, MD, Ellen M. Robertson, MD, and C. Wayne Cruse, MD Division of Plastic Surgery, Department of Surgery, University
More informationMalignant tumors of melanocytes : Part 3. Deba P Sarma, MD., Omaha
Malignant tumors of melanocytes : Part 3 Deba P Sarma, MD., Omaha Let s go over one case of melanoma using the following worksheet. Of the various essential information that needs to be included in the
More informationCharacteristics and prognostic factors of synchronous multiple primary esophageal carcinoma: A report of 52 cases
Thoracic Cancer ISSN 1759-7706 ORIGINAL ARTICLE Characteristics and prognostic factors of synchronous multiple primary esophageal carcinoma: A report of 52 cases Mei Li & Zhi-xiong Lin Department of Radiation
More informationLocoregional treatment Session Oral Abstract Presentation Saulo Brito Silva
Locoregional treatment Session Oral Abstract Presentation Saulo Brito Silva Background Post-operative radiotherapy (PORT) improves disease free and overall suvivallin selected patients with breast cancer
More informationClinico-pathological Features of Patients with Melanoma and Positive Sentinel Lymph Node Biopsy: A Single Institution Experience
2015;23(2):122-129 CLINICAL ARTICLE Clinico-pathological Features of Patients with Melanoma and Positive Sentinel Lymph Node Biopsy: A Single Institution Experience Damir Homolak 1, Mirna Šitum 2,3, Hrvoje
More informationSENTINEL LYMPH node (SLN) biopsy has become
COMMENTARY Sentinel Lymph Node Biopsy for Melanoma: Controversy Despite Widespread Agreement By Kelly M. McMasters, Douglas S. Reintgen, Merrick I. Ross, Jeffrey E. Gershenwald, Michael J. Edwards, Arthur
More informationRare Small Cell Carcinoma in Genitourinary Tract: Experience from E-Da Hospital
E-Da Medical Journal 20;():-5 Original Article Rare Small Cell Carcinoma in Genitourinary Tract: Experience from E-Da Hospital Wei-Ting Kuo, I-Wei Chang2, Kevin Lu, Hua-Pin Wang, Tsan-Jung u, Victor C.
More information